Latest news with #FASN
Yahoo
3 days ago
- Business
- Yahoo
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps
Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne vulgaris. The trial was conducted by Sagimet's license partner, Ascletis Bioscience Co. Ltd., in China. Denifanstat is a once-daily oral small-molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 for acne in China and by Sagimet for metabolic dysfunction-associated steatohepatitis (MASH) in the rest of the Sagimet recently initiated a Phase 1 first-in-human trial with a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S. The trial randomized 480 patients in China to receive either denifanstat once daily or a placebo for 12 weeks. For the primary endpoint of treatment success, defined as an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from baseline at week 12, the denifanstat group demonstrated a statistically significant 33.2% rate over the placebo group's 14.6%. Additional goals further corroborated denifanstat's efficacy versus placebo, including: Reduction in total lesion count (57.4% vs 35.4%). Reduction in inflammatory lesion count (63.5% vs 43.2%). Reduction in non-inflammatory lesion count (51.9% vs. 28.9%). Ascletis reported that denifanstat was generally well-tolerated. Following 12 weeks of once-daily oral administration at 50 mg, treatment-emergent adverse events (TEAE) incidence rates were comparable between denifanstat and placebo. All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs. No deaths were reported. These Phase 3 results confirm that FASN inhibition represents a potential therapeutic approach within acne. Ascletis has indicated that it plans to submit denifanstat for approval to the China National Medical Products Administration. Building on Ascletis' Phase 3 results, Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. In other notable pharmaceutical industry news, GSK plc (NYSE:GSK) agreed to acquire Boston Pharmaceuticals' lead asset, efimosfermin alfa, a phase 3-ready, investigational specialty medicine for treating and preventing the progression of steatotic liver disease in May. Under the agreement, GSK will pay up to $2 billion in total cash consideration, including $1.2 billion upfront, with the potential for additional success-based milestone payments totaling $800 million. This highlights ongoing investment in the liver disease space, an area where Sagimet is also active with its MASH program. Price Action: SGMT stock is trading higher by 31.7% to $4.78 premarket at last check Wednesday. Read Next:Image via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S. SAN MATEO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet's license partner Ascletis Bioscience Co. Ltd. (Ascletis) in China. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 for acne in China and by Sagimet for MASH in the rest of world. Additionally, Sagimet recently initiated a Phase 1 first-in-human clinical trial with a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the US. 'We are highly encouraged by the positive results from Ascletis' Phase 3 acne trial in China,' said David Happel, Chief Executive Officer of Sagimet. 'FASN inhibition represents a novel potential approach to treat moderate to severe acne vulgaris, a widespread condition impacting more than 640 million people worldwide. These positive data support the rationale for our development of our FASN inhibitor TVB-3567 for moderate-to-severe acne and add to the body of evidence of the broad consequences of unchecked overactivity of FASN.' 'It is very exciting to see this novel oral acne product candidate progressing through development in light of the limited innovation within the acne space over the past 40 years,' said Dr. Neal Bhatia, Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego and a past Vice President of the American Academy of Dermatology. 'These data demonstrate the significant clinical response that a FASN inhibitor can achieve for moderate to severe acne patients by addressing the overproduction of sebum and the inflammatory cascade, two of the primary pathways of acne, and most importantly through a novel mechanism of action. With currently available treatments either showing limited efficacy, high potential for irritation, or risks of antibiotic resistance, control of acne through new modes of action is more critical now than ever.' Over 50 million people suffer from acne in the US, making it one of the most prevalent skin diseases that physicians address annually. Patients with acne vulgaris have increased sebum production compared to non-acne populations which contributes to the pathogenesis of the disease. Increased sebum production is due to increased de novo lipogenesis (DNL) locally in the sebocytes. FASN is the last committed step in the DNL pathway which produces the majority (>80%) of key sebum lipids such as palmitate and sapienic acid in acne, and FASN also contributes to inflammatory pathways. Inhibition of FASN is therefore an attractive therapeutic approach to address acne. In two separate denifanstat Phase 1 clinical trials, Sagimet collected sebum as a non-invasive approach to assess FASN pharmacodynamic activity and showed that use of denifanstat led to significant reductions in sapienic acid, a sebum fatty acid produced only by de novo lipogenesis, confirming FASN inhibition. These results provided mechanistic proof of concept for FASN inhibition in sebum and provided a basis for Ascletis' successful Phase 2 and 3 clinical trials of denifanstat in acne in China. Clinical Results The Phase 3 clinical trial (NCT06192264) was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat for the treatment of patients with moderate to severe acne. The 480 enrolled patients were randomized 1:1 into two treatment arms to receive denifanstat 50mg or placebo, once daily for 12 weeks. Primary endpoints included the percentage of treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from baseline), the percentage change in total lesion count, and the percentage change in inflammatory lesion count. Ascletis reported that denifanstat met all the primary and secondary endpoints. Efficacy results are summarized in Table 1 below. Table 1: Efficacy data from Phase 3 trial of Denifanstat (ASC40) in acne vulgaris Endpoints 50mg denifanstat, oral, once daily(n=240) Placebo, oral, once daily(n=240) Placeboadjusted p value % Treatment success (IGA) 33.2 14.6 18.6 <0.0001 % Change in total lesion count -57.4 -35.4 -22.0 <0.0001 % Change in inflammatory lesion count -63.5 -43.2 -20.3 <0.0001 % Change in non-inflammatory lesion count -51.9 -28.9 -23.0 <0.0001 Absolute change in total lesion count -58.3 -36.2 -22.1 <0.0001 Absolute change in inflammatory lesion count -26.6 -18.4 -8.2 <0.0001 Source: Ascletis Press Release issued June 3rd, 2025 Ascletis reported that denifanstat was generally well-tolerated. Following 12 weeks of once-daily oral administration at 50 mg, the incidence rates of treatment-emergent adverse events (TEAE) were comparable between denifanstat and placebo. No incidence rate of TEAEs in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (dry skin and dry eye reported in 6.3% and 5.9 % of denifanstat-treated subjects versus 2.9% and 3.8% in placebo-treated subjects, respectively). All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs (SAEs). No deaths were reported. These Phase 3 results confirm that FASN inhibition represents a potential therapeutic approach within acne. Ascletis has indicated that it plans to submit denifanstat for approval to the China National Medical Products Administration. Building on Ascletis' positive Phase 3 results, Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the US. For additional information about Sagimet, please visit About Acne There are 5.1 million acne patients in the U.S. who are treated by dermatologists annually, and a total U.S. acne market of over 50 million people. 1,2 There is no cure for acne; and due to its pathology, most patients require chronic management and multiple courses of treatment for flare control annually. Additionally, adherence to topical therapies is lower than with oral agents, with an estimated 30% to 40% of patients not adhering to their topical treatments. 3 Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. Journal of the American Academy of Dermatology 2006;55:490-500. American Academy of Dermatology/Milliman. Burden of Skin Disease. 2017. Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055. Forward-Looking Statements This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet's clinical development plans and related anticipated development milestones, Sagimet's cash and financial resources and expected cash runway. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'seek,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'forecast,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet's control, including, among others: the clinical development and therapeutic potential of denifanstat or any other drug candidates Sagimet may develop; Sagimet's ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet's relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet's estimates regarding its capital requirements; and Sagimet's ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the 'Risk Factors' section of Sagimet's most recent filings with the Securities and Exchange Commission and available at You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Investor Contact:Joyce Allaire LifeSci Advisors JAllaire@ Media Contact:Michael FitzhughLifeSci Advisors mfitzhugh@
Yahoo
07-05-2025
- Business
- Yahoo
Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction-Associated Steatohepat
Bluejay Therapeutics BJT-188 demonstrated liver-specific potency with minimal exposure to other tissues The data are being presented at the European Association for the Study of the Liver (EASL) Congress 2025 REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced preclinical data on BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). BJT-188 demonstrated potent FASN inhibition in preclinical models, with reduced systemic exposure that may help minimize toxicities. BJT-188 is a product of Bluejay Therapeutics' Liver-Targeting Advanced Platform (L-TAP) that integrates molecular modeling and drug design to create novel therapeutics with optimized liver-targeted distribution profiles. The data are being presented in a poster at the European Association for the Study of the Liver (EASL) Congress 2025. The poster is also available on Bluejay's website. "MASH represents a serious and growing global health challenge,' said Hassan Javanbakht, Ph.D., Chief Scientific Officer of Bluejay Therapeutics. 'While FASN inhibitors offer therapeutic potential, many have been limited by systemic side effects. Our preclinical data suggest that BJT-188 may potentially overcome these challenges by reducing systemic exposure while maintaining therapeutic efficacy in the liver. We are now moving the program into IND-enabling studies." Preclinical Characterization of BJT-188 This study evaluated the intrinsic potency of BJT-188 versus denifanstat, an investigational FASN inhibitor, by measuring in vitro inhibition of de novo lipogenesis (DNL) in primary rat, mouse and human hepatocytes. BJT-188 inhibited DNL in primary human hepatocytes with an EC₅₀ of 20.4 ± 9.9 nM and demonstrated comparable potency in rat and mouse hepatocytes. In vivo, a single oral dose of BJT-188 in rats demonstrated rapid and preferential accumulation in the liver, with similar liver targeting observed in mice. Liver-to-plasma and liver-to-skin ratios were significantly more favorable for BJT-188 compared to denifanstat. The minimal exposure to skin and other peripheral tissues suggests a lower risk of alopecia, a side effect reported with denifanstat. Additionally, in an in vivo rat study, BJT-188 inhibited palmitate formation in a dose-dependent manner, reaching up to 98% inhibition of DNL at the highest dose tested (60 mg/kg). Palmitate is the primary fatty acid produced during DNL.
Associated Press
28-04-2025
- Business
- Associated Press
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis
Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins Underscores Radiopharm's commitment to developing transformative oncology radiopharmaceuticals SYDNEY, April 28, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its U.S. Phase 2b imaging study of 18F-RAD101 in suspected recurrent brain metastasis. The U.S. multicenter, open-label, single arm Phase 2b clinical trial1 is evaluating the diagnostic performance of 18F-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins. The primary objective of the study is concordance between 18F-RAD101 positive lesions and those seen in conventional imaging (MRI with gadolinium) in participants with suspected recurrent brain metastases. RAD101 is a novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, including cerebral metastasis. Disruption of FASN activity allows for the accurate detection of cancer cells, representing a strongly viable target for the imaging of brain metastasis. Positive data from the Imperial College of London's Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases showed significant tumor uptake that was consistent with and independent from the tumor of origin.2 'We are proud to pioneer the first U.S. clinical trial of RAD101,' said Harshad R. Kulkarni, MD, Chief Medical Advisor at BAMF Health and Principal Investigator of this Phase 2b study. 'This marks an important step toward improving diagnostic precision and enabling more evidence-based, individualized treatment decisions for patients with brain metastases following stereotactic radiosurgery.' 'This trial is an excellent illustration of BAMF Health's clinical trials platform in action,' added BAMF Health's Director of Clinical Trials. 'Our Radiopharmacy is producing the imaging agent on-site, our clinic team is caring for the patient and providing the best image in the world, and our clinical trials team expertly coordinates it all. BAMF's facility and team were built to do trials just like this.' 'Current standard of care imaging is less sensitive in discriminating between tumor recurrence and radiation necrosis in patients with brain metastasis who have received anticancer treatments, including radiation,' said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics Ltd. '18F-RAD101 has the strong potential to improve diagnostic accuracy of brain metastases, and holds promise for discriminating between treatment effect and true progression in the more than 300,000 patients diagnosed with brain metastasis each year in the U.S. alone. We look forward to advancing this clinical trial and to reporting topline data in the second half of 2025.' About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at About BAMF Health BAMF Health is the world's first vertically integrated platform for intelligence-based precision medicine. Headquartered in Grand Rapids, Michigan, BAMF Health employs the most advanced theranostic imaging technology to detect and treat cancer and other diseases and conduct advanced clinical trials. Our overriding mission is to empower patients to become people again. With a team of data scientists, researchers, software engineers, and clinicians —all working in lockstep—we're making good on it. To learn more about BAMF Health, visit Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors: Riccardo Canevari CEO & Managing Director Radiopharm Theranostics P: +1 862 309 0293 E: [email protected] Andrew Dymon Precision AQ (formerly Stern IR) [email protected] Media: Matt Wright NWR Communications P: +61 451 896 420 E: [email protected] Follow Radiopharm Theranostics: Website – Twitter – Linked In – InvestorHub – ________________________ 1 2 S. Islam et. Al., EJNMMI; 07 February 2025.
Yahoo
05-02-2025
- Business
- Yahoo
US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks
As U.S. markets respond positively to recent developments in tariffs and corporate earnings, investors are exploring various opportunities across the financial landscape. Penny stocks, often associated with smaller or newer companies, provide a unique opportunity for growth at lower price points. Despite being considered a niche investment area today, these stocks can still offer significant potential when backed by strong financial health and fundamentals. Name Share Price Market Cap Financial Health Rating BAB (OTCPK:BABB) $0.8577 $6.52M ★★★★★★ QuantaSing Group (NasdaqGM:QSG) $3.08 $121.59M ★★★★★★ ZTEST Electronics (OTCPK:ZTST.F) $0.2799 $9.75M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $3.03 $88.27M ★★★★★★ Permianville Royalty Trust (NYSE:PVL) $1.43 $47.85M ★★★★★★ Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M ★★★★★★ BTCS (NasdaqCM:BTCS) $3.09 $51.01M ★★★★★★ Smith Micro Software (NasdaqCM:SMSI) $1.35 $21.99M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.9234 $83.69M ★★★★★☆ SideChannel (OTCPK:SDCH) $0.038815 $9.04M ★★★★★★ Click here to see the full list of 707 stocks from our US Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Gevo, Inc. operates as a carbon abatement company with a market cap of $404.57 million. Operations: The company generates revenue from two segments: Gevo, with $0.96 million, and Renewable Natural Gas, contributing $14.63 million. Market Cap: $404.57M Gevo, Inc., a carbon abatement company, is navigating the penny stock landscape with notable developments. Despite being pre-revenue in its Gevo segment and unprofitable overall, it has a market cap of US$404.57 million and generates US$14.63 million from Renewable Natural Gas. The company's management and board are experienced, with average tenures of 3.3 and 6.3 years respectively, while debt levels have decreased over five years to a debt-to-equity ratio of 13.3%. Recent collaborations include extending an agreement with LG Chem for commercializing its Ethanol-to-Olefins technology targeting sustainable fuels and chemicals markets. Unlock comprehensive insights into our analysis of Gevo stock in this financial health report. Learn about Gevo's future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing fatty acid synthase (FASN) inhibitors for treating diseases caused by dysfunctional metabolic pathways in the United States, with a market cap of approximately $150.03 million. Operations: Sagimet Biosciences Inc. does not have any reported revenue segments. Market Cap: $150.03M Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, is navigating the penny stock sector with its focus on developing FASN inhibitors. The company remains pre-revenue, with no significant revenue streams and a market cap of US$150.03 million. Despite being debt-free and having short-term assets of US$157.2 million exceeding liabilities of US$4.1 million, it is unprofitable with losses widening over recent years. Recent presentations highlighted promising Phase 2b data for its lead candidate, denifanstat, showing potential benefits in treating fibrosis and cardiovascular conditions, yet profitability remains elusive in the near term as earnings are forecast to decline by 18.7% annually over three years. Click here to discover the nuances of Sagimet Biosciences with our detailed analytical financial health report. Understand Sagimet Biosciences' earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: 3D Systems Corporation offers 3D printing and digital manufacturing solutions across various regions including the Americas, Europe, the Middle East, North Africa, the Asia Pacific, and Oceania with a market cap of approximately $507.22 million. Operations: The company's revenue is derived from two primary segments: Healthcare, contributing $200.56 million, and Industrial, accounting for $243.39 million. Market Cap: $507.22M 3D Systems, with a market cap of US$507.22 million, is navigating challenges in the penny stock space. The company faces significant financial hurdles, reporting a net loss of US$178.63 million for Q3 2024 and impairment charges totaling US$143.7 million. Despite these setbacks, 3D Systems maintains sufficient cash runway for over three years and has formed strategic partnerships like the one with Daimler Buses to enhance service capabilities through remote spare part printing solutions. While currently unprofitable and experiencing high share price volatility, its experienced management team is steering efforts towards innovation in additive manufacturing technologies. Get an in-depth perspective on 3D Systems' performance by reading our balance sheet health report here. Evaluate 3D Systems' prospects by accessing our earnings growth report. Explore the 707 names from our US Penny Stocks screener here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:GEVO NasdaqGM:SGMT and NYSE:DDD. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
